Clinical efficacy of daily online image-guided stereotactic body radiation therapy for lung cancer
10.3760/cma.j.issn.1004-4221.2014.04.012
- VernacularTitle:每次在线图像引导下肺肿瘤SBRT临床疗效分析
- Author:
Hong GAO
;
Gaofeng LI
;
Qiuzi ZHONG
;
Yonggang XU
;
Qinhong WU
- Publication Type:Journal Article
- Keywords:
Lung neoplasms/radiotherapy;
Radiotherapy,stereotactic;
Radiotherapy,image-guided;
Prognosis
- From:
Chinese Journal of Radiation Oncology
2014;23(4):322-325
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the clinical efficacy of daily online cone-beam computed tomography (CBCT)-guided stereotactic body radiation therapy (SBRT) for primary and metastatic lung cancer and its related factors.Methods From May 2009 to May 2013,36 patients with lung cancer were treated with SBRT,including 24 patients with primary lung cancer and 12 patients with metastatic lung cancer.The biologically effective dose at 10 Gy was ≥ 100 Gy in 85.7％ of 42 lesions.Before each delivery,CBCT was acquired,and online automatic or manual registration was performed to make the tumors on CBCT within the planning target volume/primary gross tumor volume;the setup threshold was not set,and the couch was moved for correction.Results The 1-,2-,and 3-year sample sizes were 36,29,and 26,respectively.The 1-,2-,and 3-year local control (LC) rates were 96％,89％,and 72％,respectively.The 1-,2-,and 3-year cancer-specific survival (CCS) rates were 82％,74％,and 64％,respectively.The 1-,2-,and 3-year overall survival (OS) rates were 78％,64％,and 53％,respectively.Univariate analysis found no factors associated with LC.Multivariate analysis revealed no factors associated with OS.Both univariate and multivariate analyses showed that only tumor location (central type or peripheral type) was associated with CCS;the mean values (95％ confidence intervals) of CCS in patients with central-type and peripheral-type lesions were 21.4 months (13.2-29.6 months) and 42.3 months (35.7-49.0months),respectively (P=0.024).Conclusions Daily online image-guided SBRT for primary or metastatic lung cancer can lead to a satisfactory LC.
